Clinical Trial Update: A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating rituximab in rheumatoid arthritis patients with inadequate response to methotrexate, with trial results posted outlining outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)
• Rituxan (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2015-04-10